Now this is what you call a reversal of fortune. One year after losing 18 percent, Chris Hohn’s TCI Fund Management surged to a 33 percent gain in 2023. As a result, the London-based, ...

Hester Peirce was appointed as a Commissioner at the Securities and Exchange Commission just a year into Trump’s first term and has served as one of its leading voices now for close to seven years. A ...

Private capital is flooding into defense technology companies at unprecedented levels. Venture funds are "pouring money into defense startups," Bloomberg reports, with defense-related U.S. startups ...

Companies that manage investments for their pension plans in-house face a thankless job. The costs are high, the profits are low, and the rewards are limited. So Nokia USA shed its in-house pension ...

Greenlight Capital mostly missed the stock market’s powerful April rally. The hedge fund headed by David Einhorn rose just 60 basis points, or 0.6 percent, last month, extending its gain for the year ...

A brutal selloff of public business development companies has left investors struggling with a stark question: Are steep discounts signaling that a wave of defaults is coming or has fear run ahead of ...

Inflows into Japanese stocks and bonds surged this year, showing that measures taken by the government to improve the asset management industry are working as planned. The inflows also reflect capital ...

Private equity proponents argue that one of the asset class’s biggest selling points is its low volatility compared with public equities. But Verdad Advisers founder Dan Rasmussen, a longtime critic ...

Biopharma and life sciences hedge funds saw yet another month of stunning gains in what is shaping up to be one of the best years for any sector outside artificial intelligence. At least a half-dozen ...

KKR & Co. is deepening private equity inroads into the world of individual investors. KKR, co-founded by Henry Kravis in 1976, announced Wednesday that it has invested in iCapital Network and that ...

Things have been unexpectedly gloomy for private equity exits this year, despite earlier hopes for a resurgence in the first half. But there are signs of optimism creeping back in. The trillions of ...

Biotech doesn’t typically fail in the lab. It fails later — after early promise and before approval — when the cost of proving a drug works comes up against a funding system built for an earlier stage ...